Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis

ConclusionsA tobramycin dose of 3  mg/cm/day rather than 10 mg/kg/day achieved similar PK/PD outcomes but dose and AUC0 –24 ranges were narrower and the incidence of high AUC0 –24 values was lower. Height-based doses should therefore be considered for patients with CF.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research